Patents by Inventor Jessica L. Frie
Jessica L. Frie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220242847Abstract: The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: May 18, 2020Publication date: August 4, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Cheng Wang, Deping Wang
-
Publication number: 20220064147Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: December 13, 2019Publication date: March 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Scott D. Kuduk, Helen J. Mitchell, Philippe Nantermet, Deyou Sha, William Daniel Shipe, Cheng Wang, Deping Wang
-
Patent number: 10072003Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, L, X1, X2, and X3, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a person in need thereof for diseases or disorders in which the mGluR2-NAM receptor plays a causative role, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders.Type: GrantFiled: August 24, 2015Date of Patent: September 11, 2018Inventors: Ashok Arasappan, Christopher James Bungard, Jessica L. Frie, Yongxin Han, Scott B. Hoyt, Peter J. Manley, Robert S. Meissner, James J. Perkins, Iyassu K. Sebhat, Robert R. Wilkening, Kenneth J. Leavitt
-
Patent number: 10000454Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: May 19, 2015Date of Patent: June 19, 2018Assignee: Merck Sharp & DohmeInventors: Tesfaye Biftu, Purakkattle Biju, Timothy A. Blizzard, Zhengxia Chen, Matthew J. Clements, Mingxiang Cui, Jessica L. Frie, William K. Hagmann, Bin Hu, Hubert Josien, Anilkumar G. Nair, Christopher W. Plummer, Cheng Zhu
-
Publication number: 20170305902Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, L, X1, X2, and X3, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a person in need thereof for diseases or disorders in which the mGluR2-NAM receptor plays a causative role, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders.Type: ApplicationFiled: August 24, 2015Publication date: October 26, 2017Applicants: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: Ashok Arasappan, Christopher James Bungard, Jessica L. Frie, Yongxin Han, Scott B. Hoyt, Peter J. Manley, Robert S. Meissner, James J. Perkins, Iyassu K. Sebhat, Robert R. Wilkening, Kenneth J. Leavitt
-
Patent number: 9777002Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: GrantFiled: November 22, 2013Date of Patent: October 3, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Shawn P. Walsh, Brian Cato, Jessica L. Frie, Dooseop Kim, Alexander Pasternak, Zhi-Cai Shi
-
Patent number: 9604998Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.Type: GrantFiled: February 12, 2014Date of Patent: March 28, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Reynalda Keh DeJesus, Fa-Xiang Ding, Shuzhi Dong, Jessica L. Frie, Xin Gu, Jinlong Jiang, Aurash Shahripour, Barbara Pio, Haifeng Tang, Shawn Walsh
-
Publication number: 20170081287Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: ApplicationFiled: May 19, 2015Publication date: March 23, 2017Inventors: Tesfaye Biftu, Purakkattle Biju, Timothy A. Blizzard, Zhengxia Chen, Matthew J. Clements, Mingxiang Cui, Jessica L. Frie, William K. Hagmann, Bin Hu, Hubert Josien, Anilkumar G. Nair, Christopher W. Plummer, Cheng Zhu
-
Patent number: 9573961Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: GrantFiled: December 13, 2013Date of Patent: February 21, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Reynalda Keh DeJesus, Jessica L. Frie, Barbara Pio, Haifeng Tang, Shawn P. Walsh
-
Publication number: 20160002259Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.Type: ApplicationFiled: February 12, 2014Publication date: January 7, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Reynalda Keh DeJesus, Fa-Xiang Ding, Shuzhi Dong, Jessica L. Frie, Xin Gu, Jinlong Jiang, Aurash Shahripour, Barbara Pio, Haifeng Tang, Shawn Walsh
-
Publication number: 20150329557Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: ApplicationFiled: December 13, 2013Publication date: November 19, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Reynalda Keh DeJesus, Jessica L. Frie, Barbara Pio, Haifeng Tang, Shawn P. Walsh
-
Publication number: 20150299198Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: ApplicationFiled: November 22, 2013Publication date: October 22, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Shawn P. Walsh, Brian Cato, Jessica L. Frie, Dooseop Kim, Alexander Pasternak, Zhi-Cai Shi
-
Patent number: 9139585Abstract: This invention relates to compounds of Formula I-VI having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: GrantFiled: October 25, 2012Date of Patent: September 22, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Shawn P. Walsh, Alexander Pasternak, Reynalda K. DeJesus, Haifeng Tang, Barbara Pio, Aurash Shahripour, Kevin M. Belyk, Harry R. Chobanian, Yan Guo, Jessica L. Frie, Zhi-Cai Shi, Helen Chen, Timothy A. Blizzard, Brian Cato
-
Publication number: 20140309213Abstract: This invention relates to compounds of Formula I-VI having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH2)n1— and —(CH2)n2—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: ApplicationFiled: October 25, 2012Publication date: October 16, 2014Inventors: Shawn P. Walsh, Alexander Pasternak, Reynalda K. DeJesus, Haifeng Tang, Barbara Pio, Aurash Shahripour, Kevin M. Belyk, Harry R. Chobanian, Yan Guo, Jessica L. Frie, Zhi-Cai Shi, Helen Chen, Timothy A. Blizzard, Brian Cato